Mounjaro(Tirzepatide) Instructions:Uses,Dosage, Side Effects

1 / 1

Mounjaro(Tirzepatide)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Eli Lilly and Company

Formulation:

INJECTION

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

MOUNJARO (tirzepatide) is a novel injectable medication designed for the treatment of type 2 diabetes mellitus in adults. It works by acting on two incretin hormones, GIP and GLP-1, to regulate insulin secretion and glucose production. This dual receptor agonist has been shown to significantly improve blood sugar control in clinical trials. MOUNJARO is administered subcutaneously once a week and is intended for use in combination with diet and exercise to achieve optimal glycemic control.

As a cutting-edge therapy, MOUNJARO has demonstrated promising results in managing type 2 diabetes by not only improving blood sugar levels but also supporting weight loss. It offers an important option for patients who have not achieved sufficient control with other diabetes medications. Its efficacy and safety profile make it a valuable treatment choice for many individuals with type 2 diabetes.

Generic name

Mounjaro(Tirzepatide)

English name

Tirzepatide

Alternative Names

Mounjaro

Drug prices

Indications

MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Therapeutic Target

MOUNJARO targets both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors, functioning as a dual receptor agonist to improve glycemic control.

Active Ingredients

Tirzepatide

Dosage form

INJECTION

specifications

10mg*1vial/box

Description

MOUNJARO contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. The solution appears clear and colorless to slightly yellow.

Dosage and Administration

1. Dosage:

1.1 Starting dosage: 2.5 mg injected subcutaneously once weekly (primarily for initiation to reduce gastrointestinal adverse reactions, not intended for glycemic control)

1.2 After 4 weeks: Increase to 5 mg subcutaneously once weekly

1.3 For additional glycemic control: Increase dosage in 2.5 mg increments after at least 4 weeks on the current dose

1.4 Maximum dosage: 15 mg subcutaneously once weekly

2. Administration Instructions:

2.1 Administer once weekly, any time of day, with or without meals

2.2 Inject subcutaneously in the abdomen, thigh, or upper arm

2.3 Rotate injection sites with each dose

2.4 If a dose is missed, administer as soon as possible within 4 days (96 hours) after the missed dose

2.5 The day of weekly administration can be changed if necessary, as long as time between two doses is at least 3 days (72 hours)

CATEGORY NAVIGATION